GlycoMimetics Crecimiento futuro

Future controles de criterios 2/6

Se prevé que los beneficios de GlycoMimetics disminuyan a un ritmo anual de 13.6%, mientras que sus ingresos anuales crecerán a un ritmo de 67.8% por año. Se espera que el BPA disminuya en un 8.8% al año.

Información clave

-14.1%

Tasa de crecimiento de los beneficios

-9.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.4%
Tasa de crecimiento de los ingresos	71.7%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	06 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:GKO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1	-48	-59	N/A	4
12/31/2025	3	-42	-42	N/A	4
12/31/2024	N/A	-41	-41	N/A	4
3/31/2024	0	-37	-34	-34	N/A
12/31/2023	0	-37	-35	-35	N/A
9/30/2023	N/A	-38	-35	-35	N/A
6/30/2023	N/A	-37	-35	-35	N/A
3/31/2023	0	-42	-44	-44	N/A
12/31/2022	0	-47	-47	-46	N/A
9/30/2022	0	-54	-51	-51	N/A
6/30/2022	0	-63	-60	-60	N/A
3/31/2022	0	-64	-57	-57	N/A
12/31/2021	1	-63	-58	-57	N/A
9/30/2021	1	-62	-54	-54	N/A
6/30/2021	2	-58	-49	-49	N/A
3/31/2021	2	-58	-50	-50	N/A
12/31/2020	10	-51	-39	-39	N/A
9/30/2020	10	-50	-42	-42	N/A
6/30/2020	9	-50	-44	-44	N/A
3/31/2020	9	-51	-41	-41	N/A
12/31/2019	N/A	-58	-52	-52	N/A
9/30/2019	N/A	-57	-49	-49	N/A
6/30/2019	N/A	-55	-46	-46	N/A
3/31/2019	N/A	-51	-48	-47	N/A
12/31/2018	N/A	-48	-43	-43	N/A
9/30/2018	N/A	-44	-42	-42	N/A
6/30/2018	N/A	-40	-38	-38	N/A
3/31/2018	N/A	-37	-31	-31	N/A
12/31/2017	N/A	-33	N/A	-30	N/A
9/30/2017	N/A	-32	N/A	-27	N/A
6/30/2017	0	-32	N/A	-29	N/A
3/31/2017	0	-32	N/A	-30	N/A
12/31/2016	0	-32	N/A	-30	N/A
9/30/2016	0	-32	N/A	-31	N/A
6/30/2016	0	-32	N/A	-10	N/A
3/31/2016	20	-13	N/A	-9	N/A
12/31/2015	20	-13	N/A	-8	N/A
9/30/2015	20	-11	N/A	-7	N/A
6/30/2015	20	-11	N/A	-26	N/A
3/31/2015	15	-13	N/A	-10	N/A
12/31/2014	15	-11	N/A	-4	N/A
9/30/2014	15	-8	N/A	-4	N/A
6/30/2014	15	-5	N/A	-2	N/A
3/31/2014	0	-16	N/A	-14	N/A
12/31/2013	4	-11	N/A	-16	N/A
9/30/2013	8	-6	N/A	-13	N/A
6/30/2013	12	-2	N/A	-12	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que GKO siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que GKO siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que GKO siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (71.7% al año) de GKO crezcan más rápidamente que los del mercado German (5.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (71.7% al año) de GKO crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de GKO se prevé que sea elevada dentro de 3 años.

GlycoMimetics Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2025

Recent updates

New major risk - Financial position

New major risk - Revenue and earnings growth

New minor risk - Profitability

No longer forecast to breakeven

GlycoMimetics, Inc. to Report Q1, 2024 Results on May 09, 2024

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

New minor risk - Profitability

GlycoMimetics, Inc. to Report Q4, 2023 Results on Mar 27, 2024

GlycoMimetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

New minor risk - Share price stability

Senior VP & Chief Medical Officer recently bought €85k worth of stock

GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

New minor risk - Market cap size

GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

No longer forecast to breakeven

Full year 2022 earnings released: US$0.89 loss per share (vs US$1.23 loss in FY 2021)

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

Forecast to breakeven in 2025

Chief Medical Officer recently bought €234k worth of stock

GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$0 (vs US$0.34 loss in 3Q 2021)

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.28 loss in 2Q 2021)

GlycoMimetics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

GlycoMimetics Receives a Notice from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2021)

Insufficient new directors

GlycoMimetics, Inc. to Report Q1, 2022 Results on Apr 28, 2022

GlycoMimetics, Inc., Annual General Meeting, May 18, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

GlycoMimetics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

GlycoMimetics, Inc. Appoints Bruce Johnson as Senior Vice President and Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Independent Director recently bought €72k worth of stock

GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

GlycoMimetics, Inc. Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 3000E Value Index

GlycoMimetics, Inc. Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation

First quarter 2021 earnings released: US$0.28 loss per share (vs US$0.18 loss in 1Q 2020)

Senior VP of Clinical Development & Chief Medical Officer has left the company

Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML

Revenue beats expectations

New 90-day low: €2.82

GlycoMimetics, Inc. Announces Resignation of Helen Thackray as Senior Vice President and Chief Medical Officer

New 90-day high: €3.42

GlycoMimetics Program Data to be Highlighted Via Three Oral Presentations and Two Posters at 62nd American Society of Hematology Annual Meeting and Exposition

GlycoMimetics, Inc. to Report Q3, 2020 Results on Nov 06, 2020

New 90-day low: €2.50

GlycoMimetics, Inc. Presents New Pediatric and Secondary Endpoint Data from Rivipansel Phase 3 Reset Trial at the Annual Scientific Conference on Sickle Cell and Thalassemia Meeting

FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease

New 90-day low: €2.64

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 2500 Growth Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento